Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-25

Study Completion Date

2022-01-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to use 2 devices to compare the difference in the amount of time it takes for each device to register complete muscle relaxation after the muscle relaxing medication is given. The comparison will be made by using electromyographic (EMG), such as TetraGraph, and acceloromyographic (AMG), such as TOFScan, monitors at the time of insertion of breathing tube.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Electromyographic Assessment of the TetraGraph in Normal Volunteers

NCT02912039

Neuromuscular Blockade

COMPLETED

Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting

NCT04352140

Residual Neuromuscular Blockade

COMPLETED NA

Clinical Evaluation of a Novel Neuromuscular Blockade Monitoring System

NCT04406740

Anesthesia

TERMINATED

Train of Four Motor Point Stimulation and Monitoring

NCT02591108

Observation of Neuromuscular Block

WITHDRAWN NA

Neuromuscular Monitoring in Children (6 Months - 2 Years) With Electromyography and Acceleromyography

NCT06409260

Neuromuscular Blockade

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuromuscular Blockade

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dominant hand

Application of either TetraGraph or TOFScan device on dominant hand

Train of four measurement

Intervention Type DEVICE

Use of either TetraGraph or TOFScan to measure the neuromuscular blockade

Non-Dominant hand

Application of either TetraGraph or TOFScan device on non-dominant hand

Train of four measurement

Intervention Type DEVICE

Use of either TetraGraph or TOFScan to measure the neuromuscular blockade

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Train of four measurement

Use of either TetraGraph or TOFScan to measure the neuromuscular blockade

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients willing to participate and provide an informed consent.
* Patients undergoing elective surgical procedures that require use of NMBA agents (rocuronium) administered intraoperatively.

Exclusion Criteria

* Patients with disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, Dupuytren contracture, or any similar wrist injury.
* Patients with systemic neuromuscular diseases such as myasthenia gravis.
* Patients with significant organ dysfunction that can significantly affect pharmacokinetics of neuromuscular blocking and reversal agents; i.e., severe renal impairment or end-stage liver disease.
* Patients having surgery that would involve prepping the arm into the sterile field.
* Patients receiving a rapid sequence induction.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No